Northwest Biotherapeutics, Inc (OTCMKTS:NWBO) passed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $0.23 and traded as low as $0.25. Northwest Biotherapeutics shares last traded at $0.25, with a volume of 137,975 shares changing hands.
Separately, ValuEngine upgraded Northwest Biotherapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st.
The firm has a fifty day moving average of $0.23 and a 200 day moving average of $0.27.
Northwest Biotherapeutics, Inc, a biotechnology company, discovers and develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer.
Featured Article: Operating Income
Receive News & Ratings for Northwest Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Northwest Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.